RMTG Stock Overview
Regenerative Medical Technology Group Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Regenerative Medical Technology Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$0.075 |
| 52 Week Low | US$0.0073 |
| Beta | 1.13 |
| 1 Month Change | -4.76% |
| 3 Month Change | 9.13% |
| 1 Year Change | 219.49% |
| 3 Year Change | -88.12% |
| 5 Year Change | 52.75% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RMTG | US Specialty Retail | US Market | |
|---|---|---|---|
| 7D | -16.6% | -1.8% | -0.4% |
| 1Y | 219.5% | 16.1% | 24.8% |
Return vs Industry: RMTG exceeded the US Specialty Retail industry which returned 15.4% over the past year.
Return vs Market: RMTG exceeded the US Market which returned 23.9% over the past year.
Price Volatility
| RMTG volatility | |
|---|---|
| RMTG Average Weekly Movement | 58.3% |
| Specialty Retail Industry Average Movement | 7.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RMTG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RMTG's weekly volatility (58%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1 | Dave Christensen | regenmedtechgroup.com |
Regenerative Medical Technology Group Inc. engages in the stem cell therapy business in the United States and internationally. It provides CELLGENIC FLOW EXOSOMES for hair loss and pain management; CELLGENIC Mesenchymal Stem Cell, which excretes growth factors, cytokines, and proteins for regeneration of tissue; CELLGENIC LYOPHILIZED EXOSOMES that is derived from human umbilical cord mesenchymal stem cells, including potent growth factors, peptides, coenzymes, minerals, amino acids, vitamins and UV radiation reducing agents for skin revitalization; and VITANOVAS that offers in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. The company also offers GCELL, a closed-system medical device to harness the natural and restorative capabilities of adipose tissue; CELLGENIC SVF, an isolation kit system that has the ingredients and consumables for the extraction of adipose-derived stem cells from fat; CELLGENIC BONE MARROW; CELLGENIC Platelet Rich Plasma for healing and reducing inflammation; CELLGENIC HUMAN PLACENTA; and CELLGENIC ALLOGENEIC PRP.
Regenerative Medical Technology Group Inc. Fundamentals Summary
| RMTG fundamental statistics | |
|---|---|
| Market cap | US$470.21k |
| Earnings (TTM) | -US$5.18m |
| Revenue (TTM) | US$3.21m |
0.1x
P/S Ratio-0.1x
P/E RatioIs RMTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMTG income statement (TTM) | |
|---|---|
| Revenue | US$3.21m |
| Cost of Revenue | US$934.55k |
| Gross Profit | US$2.28m |
| Other Expenses | US$7.46m |
| Earnings | -US$5.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 70.91% |
| Net Profit Margin | -161.28% |
| Debt/Equity Ratio | -74.0% |
How did RMTG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:42 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regenerative Medical Technology Group Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|